Abstract: Some (16.7%) had mutations of unknown clinical significance (rtV207M/L/I) and only 4 patients had rtA181A/S, rtA194S or M250I.
[Long-term clevudine therapy in nucleos(t)ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
PMID: 19581770
2009
The Korean journal of hepatology
Abstract: Proven sites of mutation of HBV DNA polymerase in naive patients were, for example, L80I, L180M, A181V/T, M204I and V207I.
Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.
PMID: 15872296
2005
Journal of clinical microbiology
Abstract: The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro.
Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
PMID: 14987532
2004
Enfermedades infecciosas y microbiologia clinica
Abstract: Wild-type strains together with either the rtM204I (M552I) or rtV207I (V555I) point mutation were found in two of these cases, and the rtV207I mutation alone was detected in the third.
HBV mutation literature information.
PMID: 
2009
Alimentary pharmacology & therapeutics
Browser Board
Co-occurred Entities
Filtrator
ViMRT